| Document |
Document Title |
|
WO/2024/069180A2 |
Provided herein are multivalent protein scaffolds useful as therapeutics, and useful in identifying new therapeutic compounds. The invention also relates to multi-domain polypeptide constructs having multiple binding domains and a struct...
|
|
WO/2024/068990A1 |
The present invention relates to a chimeric helper nucleic acid molecule comprising helper elements from three distinct helper viruses, helper-free virus methods and systems for producing infectious recombinant adeno-associated virus (rA...
|
|
WO/2024/071039A1 |
The present disclosure provides a pharmaceutical composition for treating or preventing T cell-related disorders, the pharmaceutical composition containing induced regulatory T cells having high functionality and a stable immunosuppressi...
|
|
WO/2024/068768A1 |
The present application relates to Leishmania host cells, methods of engineering Leishmania host cells, methods of culturing Leishmania host cells, methods of making a polypeptide of interest using a Leishmania host cell, and polypeptide...
|
|
WO/2024/031034A9 |
The present application relates to IL-15Rα and Fc fusion protein, IL-15 and IL-15Rα heterodimeric protein, and isolated nucleic acid molecule encoding any of the fusion protein or the heterodimeric protein, vectors and host cells compr...
|
|
WO/2024/068934A1 |
The present invention provides an otic neural progenitor (ONP) cell culture substrates comprising a protein matrix composed of laminin (211), laminin (521) and laminin (111), where the amounts of laminin (211), the laminin (521) and the ...
|
|
WO/2024/073482A1 |
The present disclosure relates to multispecific antibodies, as well as polynucleotides, vectors, host cells, pharmaceutical compositions, methods of use, and methods production related thereto. In some embodiments, the multispecific anti...
|
|
WO/2024/072882A1 |
Provided herein are vectors including a polynucleotide encoding an α9L9'T protein, pharmaceutical compositions including the vector including a polynucleotide encoding an α9L9'T protein, and methods of use thereof. The methods of use i...
|
|
WO/2024/068999A1 |
The present invention provides a pharmaceutical composition comprising NFL-TBS40-63 peptide, biologically active variants or pharmaceutically acceptable salts thereof, an alanine and pharmaceutically acceptable excipients, wherein the al...
|
|
WO/2024/071279A1 |
Provided is a super-high-molecular gamma-polyglutamic acid having an average molecular weight of at least 20 million. Also provided is a Bacillus genus bacterium variant strain that can produce said super-high-molecular γ-PGA. Further p...
|
|
WO/2024/071924A1 |
In one embodiment of the present invention, the present invention relates to an exosome and uses thereof, the exosome comprising a protein that induces cell death and a polypeptide that increases the half-life of an exosome. The exosome ...
|
|
WO/2024/068753A1 |
The present application relates to glycoengineered bifunctional degraders, populations of glycoengineered bifunctional degraders, Leishmania host cells for producing glycoengineered bifunctional degraders, methods of engineering said Lei...
|
|
WO/2024/069028A1 |
The invention relates to a chimeric protein containing peptides that protect against infection by the pathogen Anaplasma phagocytophilum. The chimeric antigen comprises epitopes of Anaplasma phagocytophilum MSP4 protein, specifically fou...
|
|
WO/2024/067682A1 |
The present application relates to a genetically modified immune cell for expressing a recombinant human CD16 protein. The recombinant human CD16 protein has additions, deletions and replacements of, or any combination of the additions, ...
|
|
WO/2024/068705A1 |
The present invention generally relates to novel protease-activatable interleukin-2 (IL-2) polypeptides and immunoconjugates comprising (i) an IL-2 polypeptide, (ii) a masking moiety and (iii) a linker comprising a first protease cleavag...
|
|
WO/2024/071544A1 |
The present invention relates to a recombinant Fc receptor and cells comprising same, and has cleavage resistance to ADAM17 through amino acid modification of an ADAM17 cleavage site in a CD16 polypeptide, and can improve binding affinit...
|
|
WO/2024/067662A1 |
A triple-receptor agonist. The agonist comprises a polypeptide represented by formula (I), X 1X 2X 3GTX 6TSDYSIX 13X 14DX 16X 17X 18X 19X 20X 21FX 23X 24X 25LX 27X 28GGPSSGAPPPS (I), wherein X 1 is Y or H; X 2 is Aib; X 3 is Q or H; X 6 ...
|
|
WO/2024/072820A1 |
In alternative embodiments, provided are compositions, including compositions, products of manufacture and kits, and methods, for manipulating, and in particular, augmenting or increasing, T cell activity in vitro and in vivo, by for exa...
|
|
WO/2024/067725A1 |
Provided are a respiratory syncytial virus subtype B (RSV-B) recombinant F protein, a polynucleotide, a nucleic acid construct, an expression vector, a host cell, a stabilized trimer of the recombinant F protein, and an immunogenic compo...
|
|
WO/2024/073766A2 |
ASFV is a devastating disease for swine for which there is no treatment or vaccine. The present disclosure provides immunological compositions and methods related to the production and administration of such compositions to reduce the se...
|
|
WO/2024/066780A1 |
Provided are a fusion type adeno-associated virus and a gene delivery effect thereof in the lung and eyes. The fusion type adeno-associated virus comprises a fusion peptide fragment formed by fusion of peptide fragments of serotype AAV1 ...
|
|
WO/2024/073587A1 |
Compounds and methods for inhibiting Nrf2 by activating KEAP1.
|
|
WO/2024/069175A1 |
The present invention relates to clostridial neurotoxins engineered to comprise an endosomal protease cleavage site within the activation loop, wherein cleavage at said site produces an active di-chain clostridial neurotoxin. The inventi...
|
|
WO/2024/067796A1 |
Provided are a non-human animal expressing a human or chimeric (e.g. humanized) IL5 and/or IL5RA protein, and a use method therefor.
|
|
WO/2024/071368A1 |
The present invention provides an adjuvant and a transmucosal vaccine that are highly capable of inducing secretory IgA in addition to serum IgA and IgG when transmucosally administered. The invention relates to the adjuvant that compr...
|
|
WO/2024/073583A1 |
The invention comprises anti-ROR1 chimeric antigen receptor (CAR) T cells (CAR-T cells) natural killer cells (CAR-NK cells), compositions comprising the cells and methods of making and using the same, including methods of treatment of RO...
|
|
WO/2024/069176A1 |
The present invention relates to clostridial neurotoxins engineered to comprise an exogenous protease cleavage site within a modified activation loop, wherein cleavage at said site produces an active di-chain clostridial neurotoxin. The ...
|
|
WO/2024/066941A1 |
Provided is a composition for detecting bladder cancer. The composition comprises a detection reagent for detecting at least one of the following methylation sites: cg00206063, cg03278514, and cg13314394. Also provided are use of the com...
|
|
WO/2024/073440A1 |
Provided herein, inter alia, are methods and compositions for engineering T cells. The methods include contacting a T cell with a nucleic acid and one or more cyclic GMP- AMP synthase (cGAS) - stimulator of interferon gene (STING) pathwa...
|
|
WO/2024/073397A1 |
This invention relates synthetic tetraspanin proteins comprising a heterologous protein or fragment thereof inserted within the second extracellular loop of a tetraspanin backbone, wherein the heterologous protein or fragment thereof is ...
|
|
WO/2023/150696A9 |
Provided is a recombinant milk protein for delivery of a hydrophobic bioactive agent, a composition comprising such recombinant milk protein, and a method for using such composition.
|
|
WO/2024/071401A1 |
The present inventors found that enhancement of Plk1 activity induces lethal chromosome dynamic abnormalities in cancer cells and inhibits the proliferation thereof. Thus, activation of Plk1 and exacerbation of chromosome instability can...
|
|
WO/2024/067785A1 |
Provided is use for the treatment of chronic hepatitis B based on an interferon synergistic immune checkpoint blocking antibody. Specifically, provided is a fusion protein, comprising a PDL1-binding polypeptide and an interferon IFN whic...
|
|
WO/2024/072224A2 |
The present invention relates to a peptide-based compound for complexing and stabilizing a double stranded oligonucleotide, the compound comprising a structure p-x-b-x'-p'; wherein: i. p and p' each refer to an oligonucleotide-binding mo...
|
|
WO/2024/073043A1 |
Provided herein are methods, compositions, and kits related to using a CpG binding protein. In one embodiment, the present disclosure includes methods, compositions, and kits related to using a CpG binding protein with a cytidine deamina...
|
|
WO/2024/069240A2 |
Provided herein are methods of treating cancer (e.g., CD38-expressing cancer such as multiple myeloma) using a CD38-binding fusion protein comprising an anti-CD38 antibody fused to one or more attenuated interferon alpha-2b protein in co...
|
|
WO/2024/065882A1 |
An amino acid-based multifunctional water-based liquid, a preparation method therefor and a use thereof. In the water-based liquid, water is used as a solvent, and viscous droplets rich in amino acids, oligopeptides or/and amino acid/oli...
|
|
WO/2024/069527A1 |
Phage for the specific capture of the SARS-CoV-2 virus, said phage being an M13 phage engineered to display on the P8 protein of its coat either FHKGGYEKTWKLGD sequence peptides or EFTSKAR sequence peptides, said peptides having speci fi...
|
|
WO/2024/069010A1 |
Subject matter of the present invention is a delivery vector comprising a DNA sequence encoding pre-prodynorphin or pre-prodynorphin-variants and wherein said delivery vector drives expression of a pre- propeptide in a target cell, and w...
|
|
WO/2024/071964A1 |
The present invention relates to: a fusion polypeptide in which a His tag is fused with a peptide tag having main amino acids composed of charged and polar amino acids; a fusion protein in which the fusion polypeptide is fused with a tar...
|
|
WO/2024/071362A1 |
The present invention addresses the problem of providing a new method for improving the delivery efficiency of a drug such as a nucleic acid drug to the nervous system. Provided is a delivery enhancer for enhancing the delivery of a dr...
|
|
WO/2024/071957A1 |
The present invention relates to an amorphous peptide tag with main amino acids composed of charged and hydrophobic amino acids, a fusion protein in which the tag is fused with a target protein, and a method for purifying the target prot...
|
|
WO/2024/072985A1 |
Disclosed are methods of treating and/or inhibiting an intramammary infection in a mammalian subject. The methods included administering a therapeutically effective amount of surface-associated polypeptides from various bacteria. Also di...
|
|
WO/2024/069549A1 |
The present disclosure relates generally to vaccine constructs comprising a polynucleotide encoding a salmon alphavirus-like particle and uses thereof, including for inducing an immune response against salmonid alphavirus.
|
|
WO/2024/071970A1 |
The present invention relates to: a fusion polypeptide comprising a His tag, and a peptide tag of which the main amino acids are charged amino acids; a fusion protein in which the fusion polypeptide and a target protein are fused; and a ...
|
|
WO/2024/068827A1 |
The invention relates to a method for manufacturing a precipitated mixture, which contains liraglutide or a salt thereof (component (A)), comprising the steps of removing solid parts, mixing with an antisolvent, stirring precipitation su...
|
|
WO/2024/067153A1 |
Provided are a nucleic acid for producing rAAV in an insect cell, a VP1 capsid protein mutant, and use. The nucleic acid comprises nucleotide sequences encoding adeno-associated viruses VP1, VP2, and VP3 proteins. Compared with the capsi...
|
|
WO/2024/073606A1 |
Methods for improving engraftment of donor cells in a subject thereof are provided. Such methods can comprise providing donor cells that have been modified to express a first isoform of a target protein (e.g., interleukin-2 receptor subu...
|
|
WO/2024/067723A1 |
A respiratory syncytial virus subtype A (RSV-A) recombinant F protein, a polynucleotide, a nucleic acid construct, an expression vector, a host cell, a stabilized trimer formed by the recombinant F protein, an immunogenic composition com...
|
|
WO/2024/068617A1 |
The present invention concerns a modified cell comprising a transgene coding for interleukin-2 (IL-2). Said modified cell comprises a first vector comprising a sequence coding for IL-2 under the control of an inducible or constitutive pr...
|
